Primary Outcome Measures
- prediction of immunotherapy response with SUVmax measured with Ga-68 FAPI PET before immunotherapy
- prediction of immunotherapy response with total FAPI volume measured with Ga-68 FAPI PET before immunotherapy
- prediction of immunotherapy response with total lesion FAPI uptake measured with Ga-68 FAPI PET before immunotherapy
Inclusion Criteria
- Having a histopathologically confirmed diagnosis of
- Pleural Mesolthelioma
- Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy
- Patients who gave informed consent form to participate in the study
Exclusion Criteria
- ECOG>2
- Patients who did not provide informed consent form to participate in the study
